Leprosy as a model of immunity

Future Microbiology

Volumn 9, Issue 1, 2014, Pages 43-54

  Degang, Yang ^a,b   Nakamura, Kazuaki ^a,c   Akama, Takeshi ^a   Ishido, Yuko ^a   Luo, Yuqian ^a   Ishii, Norihisa ^a   Suzuki, Koichi ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Shanghai Dermatological and Venereal Hospital   (China)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

immunity; lepra reaction; leprosy; macrophage; Mycobacterium leprae

Indexed keywords

BACTERIAL SURVIVAL; CELLULAR IMMUNITY; ERYTHEMA NODOSUM LEPROSUM; HOST CELL; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOCALIZATION; LEPROSY; MICROBIAL DEGRADATION; MYCOBACTERIUM LEPRAE; NONHUMAN; PARASITISM; PRIORITY JOURNAL; REVERSAL REACTION; REVIEW; SCHWANN CELL; T LYMPHOCYTE;

HOST-PATHOGEN INTERACTIONS; HUMANS; LEPROSY; LIVER; MACROPHAGES; MYCOBACTERIUM LEPRAE; SCHWANN CELLS;

EID: 84890578487     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.140     Document Type: Review

References (123)

1. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8(12), 958-969 (2008).
2. Birdi TJ, Antia NH. The macrophage in leprosy: A review on the current status. Int. J. Lepr. Other Mycobact. Dis. 57(2), 511-525 (1989).
3. Stoner GL. Importance of the neural predilection of Mycobacterium leprae in leprosy. Lancet 2(8150), 994-996 (1979).
4. Mukherjee R, Antia NH. Intracellular multiplication of leprosy-derived mycobacteria in Schwann cells of dorsal root ganglion cultures. J. Clin. Microbiol. 21(5), 808-814 (1985).
5. WHO. Global leprosy situation, 2012. Wkly Epidemiol. Rec. 87(34), 317-328 (2012).
6. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int. J. Lepr. Other Mycobact. Dis. 34(3), 255-273 (1966).
7. Meima A, Irgens LM, van Oortmarssen GJ, Richardus JH, Habbema JD. Disappearance of leprosy from Norway: An exploration of critical factors using an epidemiological modelling approach. Int. J. Epidemiol. 31(5), 991-1000 (2002).
8. Rodrigues LC, Lockwood D. Leprosy now: Epidemiology, progress, challenges, and research gaps. Lancet Infect. Dis. 11(6), 464-470 (2011).
9. Walker SL, Lockwood DN. The clinical and immunological features of leprosy. Br. Med. Bull. 77-78, 103-121 (2006).
10. Faber WR, Leiker DL, Nengerman IM, Zeijlemaker WP, Schellekens PT. Lymphocyte transformation test in leprosy: Decreased lymphocyte reactivity to Mycobacterium leprae in lepromatous leprosy, with no evidence for a generalized impairment. Infect. Immun. 22(3), 649-656 (1978).
11. Godal T, Myrvang B, Froland SS, Shao J, Melaku G. Evidence that the mechanism of immunological tolerance ('central failure') is operative in the lack of host resistance in lepromatous leprosy. Scand. J. Immunol. 1(4), 311-321 (1972).
12. WHO. Recommended safety requirements for the preparation of lepromin: A WHO Memorandum. Bull. World Health Organ. 57(6), 921-923 (1979).
13. Myrvang B, Godal T, Ridley DS, Froland SS, Song YK. Immune responsiveness to Mycobacterium leprae and other mycobacterial antigens throughout the clinical and histopathological spectrum of leprosy. Clin. Exp. Immunol. 14(4), 541-553 (1973).
14. Ridley DS. Reactions in leprosy. Lepr. Rev. 40(2), 77-81 (1969).
15. Godal T. Lepra reactions. Ethiop. Med. J. 11(2), 194-195 (1973).
16. Naafs B. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Int. J. Lepr. Other Mycobact. Dis. 64(Suppl. 4), S21-S28 (1996).
17. Naafs B. Current views on reactions in leprosy. Indian J. Lepr. 72(1), 97-122 (2000).
18. Bjune G, Barnetson RS, Ridley DS, Kronvall G. Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions. Clin. Exp. Immunol. 25(1), 85-94 (1976).
19. Walker SL, Lockwood DN. Leprosy. Clin. Dermatol. 25(2), 165-172 (2007).
20. de Rijk AJ, Gabre S, Byass P, Berhanu T. Field evaluation of WHO-MDT of fixed duration, at ALERT, Ethiopia: The AMFES project - II. Reaction and neuritis during and after MDT in PB and MB leprosy patients. Lepr. Rev. 65(4), 320-332 (1994).
21. Shen J, Liu M, Zhou M, Wengzhong L. Occurrence and management of leprosy reaction in China in 2005. Lepr. Rev. 80(2), 164-169 (2009).
22. Walker SL, Nicholls PG, Dhakal S et al. A Phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment. PLoS Negl. Trop. Dis. 5(4), e1041 (2011).
23. Saunderson P. The epidemiology of reactions and nerve damage. Lepr. Rev. 71(Suppl.), S106-S110 (2000).
24. Roche PW, Theuvenet WJ, Britton WJ. Risk factors for type-1 reactions in borderline leprosy patients. Lancet 338(8768), 654-657 (1991).
25. Pocaterra L, Jain S, Reddy R et al. Clinical course of erythema nodosum leprosum: An 11 year cohort study in Hyderabad, India. Am. J. Trop. Med. Hyg. 74(5), 868-879 (2006).
26. Kahawita IP, Lockwood DN. Towards understanding the pathology of erythema nodosum leprosum. Trans. R. Soc. Trop. Med. Hyg. 102(4), 329-337 (2008).
27. Saunderson P, Gebre S, Byass P. ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: Incidence and risk factors. Lepr. Rev. 71(3), 318-324 (2000).
28. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int. J. Lepr. Other Mycobact. Dis. 72(2), 125-133 (2004).
29. Job CK, Gude S, Macaden VP. Erythema nodosum leprosum. A clinico-pathologic study. Int. J. Lepr. 32, 177-184 (1964).
30. Sehgal VN, Gautam RK, Koranne RV, Beohar PC. The histopathology of type I (lepra) and type II (ENL) reactions in leprosy. Indian J. Lepr. 58(2), 240-243 (1986).
31. Wemambu SN, Turk JL, Waters MF, Rees RJ. Erythema nodosum leprosum: A clinical manifestation of the arthus phenomenon. Lancet 2(7627), 933-935 (1969).
32. Laal S, Bhutani LK, Nath I. Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum. Infect. Immun. 50(3), 887-892 (1985).
33. Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumor necrosis factor production in patients with leprosy. Infect. Immun. 60(4), 1441-1446 (1992).
34. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-Alpha and interleukin-1 beta during leprosy reactional states. Clin. Exp. Immunol. 84(1), 103-108 (1991).
35. Foss NT, De Oliveira EB, Silva CL. Correlation between TNF production, increase of plasma C-reactive protein level and suppression of T lymphocyte response to concanavalin A during erythema nodosum leprosum. Int. J. Lepr. Other Mycobact. Dis. 61(2), 218-226 (1993).
36. Santos DO, Suffys PN, Bonifacio K, Marques MA, Sarno EN. In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosum leprosum. Clin. Immunol. Immunopathol. 67(3 Pt 1), 199-203 (1993).
37. Moraes MO, Sarno EN, Almeida AS et al. Cytokine mRNA expression in leprosy: A possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand. J. Immunol. 50(5), 541-549 (1999).
38. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr. Drug Metab. 3(2), 175-187 (2002).
39. Faber WR, Iyer AM, Fajardo TT et al. Serial measurement of serum cytokines, cytokine receptors and neopterin in leprosy patients with reversal reactions. Lepr. Rev. 75(3), 274-281 (2004).
40. Iyer A, Hatta M, Usman R et al. Serum levels of interferon-gamma, tumour necrosis factor-Alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin. Exp. Immunol. 150(2), 210-216 (2007).
41. Hamerlinck FF, Klatser PR, Walsh DS, Bos JD, Walsh GP, Faber WR. Serum neopterin as a marker for reactional states in leprosy. FEMS Immunol. Med. Microbiol. 24(4), 405-409 (1999).
42. Tadesse A, Abebe M, Bizuneh E, Mulugeta W, Aseffa A, Shannon EJ. Effect of thalidomide on the expression of TNF-Alpha m-RNA and synthesis of TNF-Alpha in cells from leprosy patients with reversal reaction. Immunopharmacol. Immunotoxicol. 28(3), 431-441 (2006).
43. Jadhav VH, Patki AH, Mehta JM. Thalidomide in type-2 lepra reaction -A clinical experience. Indian J. Lepr. 62(3), 316-320 (1990).
44. Jakeman P, Smith WC. Thalidomide in leprosy reaction. Lancet 343(8895), 432-433 (1994).
45. Bromberg JS, Chavin KD, Kunkel SL. Anti-Tumor necrosis factor antibodies suppress cell-mediated immunity in vivo. J. Immunol. 148(11), 3412-3417 (1992).
46. Silva CL, Foss NT. Tumor necrosis factor in leprosy patients. J. Infect. Dis. 159(4), 787-790 (1989).
47. Britton WJ, Lockwood DN. Leprosy. Lancet 363(9416), 1209-1219 (2004).
48. Suzuki K, Akama T, Kawashima A, Yoshihara A, Yotsu RR, Ishii N. Current status of leprosy: Epidemiology, basic science and clinical perspectives. J. Dermatol. 39(2), 121-129 (2012).
49. Steinhoff U, Wand-Wurttenberger A, Bremerich A, Kaufmann SH. Mycobacterium leprae renders Schwann cells and mononuclear phagocytes susceptible or resistant to killer cells. Infect. Immun. 59(2), 684-688 (1991).
50. Lahiri R, Randhawa B, Krahenbuhl JL. Infection of mouse macrophages with viable Mycobacterium leprae does not induce apoptosis. J. Infect. Dis. 201(11), 1736-1742 (2010).
51. Hashimoto K, Maeda Y, Kimura H et al. Mycobacterium leprae infection in monocyte-derived dendritic cells and its influence on antigen-presenting function. Infect. Immun. 70(9), 5167-5176 (2002).
52. Maeda Y, Gidoh M, Ishii N, Mukai C, Makino M. Assessment of cell mediated immunogenicity of Mycobacterium leprae-derived antigens. Cell. Immunol. 222(1), 69-77 (2003).
53. Maeda Y, Tamura T, Fukutomi Y, Mukai T, Kai M, Makino M. A lipopeptide facilitate induction of Mycobacterium leprae killing in host cells. PLoS Negl. Trop. Dis. 5(11), e1401 (2011).
54. Krutzik SR, Ochoa MT, Sieling PA et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat. Med. 9(5), 525-532 (2003).
55. Schenk M, Krutzik SR, Sieling PA et al. NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat. Med. 18(4), 555-563 (2012).
56. Modlin RL. The innate immune response in leprosy. Curr. Opin. Immunol. 22(1), 48-54 (2010).
57. Degang Y, Akama T, Hara T et al. Clofazimine modulates the expression of lipid metabolism proteins in Mycobacterium leprae-infected macrophages. PLoS Negl. Trop. Dis. 6(12), e1936 (2012).
58. Imaeda T, Convit J. Electron microscope study of Mycobacterium leprae and its environment in a vesicular leprous lesion. J. Bacteriol. 83(1), 43-52 (1962).
59. Edwards RP. Electron-microscope illustrations of division in Mycobacterium leprae. J. Med. Microbiol. 3(3), 493-499 (1970).
60. Sibley LD, Franzblau SG, Krahenbuhl JL. Intracellular fate of Mycobacterium leprae in normal and activated mouse macrophages. Infect. Immun. 55(3), 680-685 (1987).
61. Moura AC, Modolell M, Mariano M. Down regulatory effect of Mycobacterium leprae cell wall lipids on phagocytosis, oxidative respiratory burst and tumour cell killing by mouse bone marrow derived macrophages. Scand. J. Immunol. 46(5), 500-505 (1997).
62. van der Wel N, Hava D, Houben D et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129(7), 1287-1298 (2007).
63. van Kooyk Y, Geijtenbeek TB. DC-SIGN: Escape mechanism for pathogens. Nat. Rev. Immunol. 3(9), 697-709 (2003).
64. Geijtenbeek TB, van Vliet SJ, Koppel EA et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. 197(1), 7-17 (2003).
65. Maeda N, Nigou J, Herrmann JL et al. The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan. J. Biol. Chem. 278(8), 5513-5516 (2003).
66. Kang BK, Schlesinger LS. Characterization of mannose receptor-dependent phagocytosis mediated by Mycobacterium tuberculosis lipoarabinomannan. Infect. Immun. 66(6), 2769-2777 (1998).
67. Fratti RA, Chua J, Vergne I, Deretic V. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc. Natl Acad. Sci. USA 100(9), 5437-5442 (2003).
68. Vergne I, Chua J, Lee HH, Lucas M, Belisle J, Deretic V. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 102(11), 4033-4038 (2005).
69. da Silva RP, Hall BF, Joiner KA, Sacks DL. CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J. Immunol. 143(2), 617-622 (1989).
70. Ishibashi Y, Arai T. Roles of the complement receptor type 1 (CR1) and type 3 (CR3) on phagocytosis and subsequent phagosome-lysosome fusion in Salmonella-infected murine macrophages. FEMS Microbiol. Immunol. 2(2), 89-96 (1990).
71. Astarie-Dequeker C, N'Diaye EN, Le Cabec V, Rittig MG, Prandi J, Maridonneau-Parini I. The mannose receptor mediates uptake of pathogenic and nonpathogenic mycobacteria and bypasses bactericidal responses in human macrophages. Infect. Immun. 67(2), 469-477 (1999).
72. Frehel C, Rastogi N. Mycobacterium leprae surface components intervene in the early phagosome-lysosome fusion inhibition event. Infect. Immun. 55(12), 2916-2921 (1987).
73. Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 97(4), 435-447 (1999).
74. Suzuki K, Takeshita F, Nakata N, Ishii N, Makino M. Localization of CORO1A in the macrophages containing Mycobacterium leprae. Acta Histochem. Cytochem. 39(4), 107-112 (2006).
75. Tanigawa K, Suzuki K, Kimura H et al. Tryptophan aspartate-containing coat protein (CORO1A) suppresses Toll-like receptor signalling in Mycobacterium leprae infection. Clin. Exp. Immunol. 156(3), 495-501 (2009).
76. Yeung T, Grinstein S. Lipid signaling and the modulation of surface charge during phagocytosis. Immunol. Rev. 219, 17-36 (2007).
77. Mattos KA, D'Avila H, Rodrigues LS et al. Lipid droplet formation in leprosy: Toll-like receptor-regulated organelles involved in eicosanoid formation and Mycobacterium leprae pathogenesis. J. Leukoc. Biol. 87(3), 371-384 (2010).
78. Mattos KA, Lara FA, Oliveira VG et al. Modulation of lipid droplets by Mycobacterium leprae in Schwann cells: A putative mechanism for host lipid acquisition and bacterial survival in phagosomes. Cell. Microbiol. 13(2), 259-273 (2011).
79. Mattos KA, Oliveira VG, D'Avila H et al. TLR6-driven lipid droplets in Mycobacterium leprae-infected Schwann cells: Immunoinflammatory platforms associated with bacterial persistence. J. Immunol. 187(5), 2548-2558 (2011).
80. Tanigawa K, Degang Y, Kawashima A et al. Essential role of hormone-sensitive lipase (HSL) in the maintenance of lipid storage in Mycobacterium leprae-infected macrophages. Microb. Pathog. 52(5), 285-291 (2012).
81. Tanigawa K, Suzuki K, Nakamura K et al. Expression of adipose differentiation-related protein (ADRP) and perilipin in macrophages infected with Mycobacterium leprae. FEMS Microbiol. Lett. 289(1), 72-79 (2008).
82. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263(5147), 678-681 (1994).
83. Godal T, Negassi K. Subclinical infection in leprosy. Br. Med. J. 3(5880), 557-559 (1973).
84. Yamamura M, Uyemura K, Deans RJ et al. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 254(5029), 277-279 (1991).
85. Jullien D, Sieling PA, Uyemura K, Mar ND, Rea TH, Modlin RL. IL 15, an immunomodulator of T cell responses in intracellular infection. J. Immunol. 158(2), 800-806 (1997).
86. Montoya D, Cruz D, Teles RM et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 6(4), 343-353 (2009).
87. Kang TJ, Chae GT. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol. Med. Microbiol. 31(1), 53-58 (2001).
88. Bochud PY, Hawn TR, Aderem A. Cutting edge: A Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J. Immunol. 170(7), 3451-3454 (2003).
89. Johnson CM, Lyle EA, Omueti KO et al. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J. Immunol. 178(12), 7520-7524 (2007).
90. Misch EA, Macdonald M, Ranjit C et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl. Trop. Dis. 2(5), e231 (2008).
91. Soilleux EJ, Sarno EN, Hernandez MO et al. DC-SIGN association with the Th2 environment of lepromatous lesions: Cause or effect?. J. Pathol. 209(2), 182-189 (2006).
92. Stein M, Keshav S. The versatility of macrophages. Clin. Exp. Allergy 22(1), 19-27 (1992).
93. Misra N, Selvakumar M, Singh S et al. Monocyte derived IL 10 and PGE2 are associated with the absence of Th 1 cells and in vitro T cell suppression in lepromatous leprosy. Immunol. Lett. 48(2), 123-128 (1995).
94. Verreck FA, de Boer T, Langenberg DM et al. Human IL 23-producing type 1 macrophages promote but IL 10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl Acad. Sci. USA 101(13), 4560-4565 (2004).
95. Sibley LD, Krahenbuhl JL. Mycobacterium leprae-burdened macrophages are refractory to activation by gamma interferon. Infect. Immun. 55(2), 446-450 (1987).
96. Sibley LD, Krahenbuhl JL. Induction of unresponsiveness to gamma interferon in macrophages infected with Mycobacterium leprae. Infect. Immun. 56(8), 1912-1919 (1988).
97. Kaplan G, Nusrat A, Sarno EN et al. Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Am. J. Pathol. 128(2), 345-353 (1987).
98. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J. Exp. Med. 175(6), 1729-1737 (1992).
99. Garcia VE, Uyemura K, Sieling PA et al. IL 18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. J. Immunol. 162(10), 6114-6121 (1999).
100. de la Barrera S, Finiasz M, Fink S et al. NK cells modulate the cytotoxic activity generated by Mycobacterium leprae-hsp65 in leprosy patients: Role of IL 18 and IL 13. Clin. Exp. Immunol. 135(1), 105-113 (2004).
101. Kaplan G, Cohn ZA. Leprosy and cell-mediated immunity. Curr. Opin. Immunol. 3(1), 91-96 (1991).
102. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 133(5), 775-787 (2008).
103. Palermo ML, Pagliari C, Trindade MA et al. Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy. Am. J. Trop. Med. Hyg. 86(5), 878-883 (2012).
104. Attia EA, Abdallah M, Saad AA et al. Circulating CD4+ CD25 high FoxP3+ T cells vary in different clinical forms of leprosy. Int. J. Dermatol. 49(10), 1152-1158 (2010).
105. Kumar S, Naqvi RA, Ali R, Rani R, Khanna N, Rao DN. CD4+CD25+ T regs with acetylated FoxP3 are associated with immune suppression in human leprosy. Mol. Immunol. 56(4), 513-520 (2013).
106. Pulendran B. Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol. Res. 29(1-3), 187-196 (2004).
107. Kalinski P, Moser M. Consensual immunity: Success-driven development of T-helper-1 and T-helper-2 responses. Nat. Rev. Immunol. 5(3), 251-260 (2005).
108. Martin-Fontecha A, Sebastiani S, Hopken UE et al. Regulation of dendritic cell migration to the draining lymph node: Impact on T lymphocyte traffic and priming. J. Exp. Med. 198(4), 615-621 (2003).
109. Sieling PA, Jullien D, Dahlem M et al. CD1 expression by dendritic cells in human leprosy lesions: Correlation with effective host immunity. J. Immunol. 162(3), 1851-1858 (1999).
110. Simoes Quaresma JA, de Oliveira MF, Ribeiro Guimaraes AC et al. CD1a and factor XIIIa immunohistochemistry in leprosy: A possible role of dendritic cells in the pathogenesis of Mycobacterium leprae infection. Am. J. Dermatopathol. 31(6), 527-531 (2009).
111. Krutzik SR, Tan B, Li H et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat. Med. 11(6), 653-660 (2005).
112. Santos DO, Castro HC, Bourguignon SC et al. Expression of B7-1 costimulatory molecules in patients with multibacillary leprosy and reactional states. Clin. Exp. Dermatol. 32(1), 75-80 (2007).
113. Murray RA, Siddiqui MR, Mendillo M, Krahenbuhl J, Kaplan G. Mycobacterium leprae inhibits dendritic cell activation and maturation. J. Immunol. 178(1), 338-344 (2007).
114. Karat AB, Job CK, Rao PS. Liver in leprosy: Histological and biochemical findings. Br. Med. J. 1(5744), 307-310 (1971).
115. Sehgal VN, Tyagi SP, Kumar S, Gupta MC, Hameed S. Microscopic pathology of the liver in leprosy patients. Int. J. Dermatol. 11(3), 168-172 (1972).
116. Crispe IN. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3(1), 51-62 (2003).
117. Crispe IN. The liver as a lymphoid organ. Annu. Rev. Immunol. 27, 147-163 (2009).
118. Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP. The liver as a site of T-cell apoptosis: Graveyard, or killing field?. Immunol. Rev. 174, 47-62 (2000).
119. Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 359(14), 1486-1500 (2008).
120. Sunderkotter C, Nikolic T, Dillon MJ et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 172(7), 4410-4417 (2004).
121. Yogi Y, Banba T, Kobayashi M et al. Leprosy in hypertensive nude rats (SHR/NCrj-rnu). Int. J. Lepr. Other Mycobact. Dis. 67(4), 435-445 (1999).
122. Dagur PK, Sharma B, Kumar G et al. Mycobacterial antigen(s) induce anergy by altering TCR-And TCR/CD28-induced signalling events: Insights into T-cell unresponsiveness in leprosy. Mol. Immunol. 47(5), 943-952 (2010).
123. Rojas-Espinosa O, Estrada-Parra S. Immunology of leprosy: Cellular anergy to Mycobacterium leprae. Arch. Invest. Med. (Mex.) 20(4), 335-341 (1989).